ADICT - Bispecific Antibody Platform with Optimization of Action Mechanism and Target Combination

Leveraging our deep understanding of the tumor microenvironment, immune cell biology, and the mechanisms of therapeutic targets, we have developed an in-house ADICT® (Antibody-Directed Immune Cell Activation at the Tumor Site) platform to enable the discovery of first-in-class bispecific antibodies with novel target combinations and mechanisms of action.

Cytotoxic T or NK cell redirection

4-1BB (CD137) is a co-stimulatory receptor widely expressed on activated T cells, natural killer (NK) cells and various other immune cell types..

4-1BB-mediated co-stimulation enhances the proliferation, cytotoxicity, and cytokine production of these immune cells and protects them from activation-induced cell death.
Effective and moderate tumor immune activation

4-1BB is highly expressed in CD8+ tumor infiltrating lymphocytes (TILs), and CD8+ TILs expressing 4-1BB are widely regarded as tumor-reactive effector T cells.

Engagement of 4-1BB effectively activates these TILs and promotes the generation of memory T cells.
Targeted delivery and enrichment of cytokines

Systemic administration of cytokines is often associated with significant toxicity. Targeted delivery and localized enrichment of cytokines can enhance their anti-tumor efficacy while reducing systemic toxicity.